Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $5.95 in the last session, up 7.01% from day before closing price of $5.56. In other words, the price has increased by $7.01 from its previous closing price. On the day, 1.19 million shares were traded. TRVI stock price reached its highest trading level at $6.0 during the session, while it also had its lowest trading level at $5.515.
Ratios:
We take a closer look at TRVI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.41 and its Current Ratio is at 10.41. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on March 10, 2025, Upgraded its rating to Strong Buy and sets its target price to $29 from $9 previously.
On March 10, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $8 to $25.
H.C. Wainwright reiterated its Buy rating for the stock on December 12, 2024, while the target price for the stock was revised from $6 to $7.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 575259072 and an Enterprise Value of 468669248.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.69, which has changed by 1.2326455 over the last 52 weeks, in comparison to a change of 0.07019031 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $7.39, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 12.39%, while the 200-Day Moving Average is calculated to be 59.72%.
Shares Statistics:
According to the various share statistics, TRVI traded on average about 2.09M shares per day over the past 3-months and 1894760 shares per day over the past 10 days. A total of 93.60M shares are outstanding, with a floating share count of 57.14M. Insiders hold about 40.90% of the company’s shares, while institutions hold 45.70% stake in the company. Shares short for TRVI as of 1743379200 were 5503093 with a Short Ratio of 2.63, compared to 1740700800 on 3791658. Therefore, it implies a Short% of Shares Outstanding of 5503093 and a Short% of Float of 7.9399999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
